Journal
FRONTIERS IN IMMUNOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2022.955035
Keywords
alopecia areata; JAK; STAT; JAK inhibition; cytokines; clinical trials
Categories
Funding
- Department of Veterans Affairs (VA Merit Award) [I01 BX004907]
- National Institutes of Health [R01 AR077194, K08 AR069111]
- University of Iowa Department of Dermatology
Ask authors/readers for more resources
Alopecia Areata (AA) is a common autoimmune disease characterized by hair loss. The breakdown of immune privilege of the hair follicle plays a role in the development of the disease. IFN gamma and other cytokines are involved in the pathogenesis of AA. Targeting the JAK/STAT signaling pathways has been shown to be effective in treating the disease.
Alopecia Areata (AA) is a common autoimmune disease characterized by non-scarring hair loss ranging from patches on the scalp to complete hair loss involving the entire body. Disease onset is hypothesized to follow the collapse of immune privilege of the hair follicle, which results in an increase in self-peptide/MHC expression along the follicular epithelium. Hair loss is associated with infiltration of the hair follicle with putatively self-reactive T cells. This process is thought to skew the hair follicle microenvironment away from a typically homeostatic immune state towards one of active inflammation. This imbalance is mediated in part by the dominating presence of specific cytokines. While interferon-gamma (IFN gamma) has been identified as the key player in AA pathogenesis, many other cytokines have also been shown to play pivotal roles. Mechanistic studies in animal models have highlighted the contribution of common gamma chain (gamma(c)) cytokines such as IL-2, IL-7, and IL-15 in augmenting disease. IFN gamma and gamma(c) cytokines signal through pathways involving receptor activation of Janus kinases (JAKs) and signal transducers and activators of transcription (STATs). Based on these findings, JAK/STAT pathways have been targeted for the purposes of therapeutic intervention in the clinical setting. Case reports and series have described use of small molecule JAK inhibitors leading to hair regrowth among AA patients. Furthermore, emerging clinical trial results show great promise and position JAK inhibitors as a treatment strategy for patients with severe or recalcitrant disease. Demonstrated efficacy from large-scale clinical trials of the JAK inhibitor baricitinib led to the first-in-disease FDA-approved treatment for AA in June of 2022. This review aims to highlight the JAK/STAT signaling pathways of various cytokines involved in AA and how targeting those pathways may impact disease outcomes in both laboratory and clinical settings.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available